Company Overview and News

0
Kansai Nerolac Q1 net falls to Rs 139.84 cr

10h freepressjournal.in
New Delhi : Kansai Nerolac Paints on Friday reported a marginal decline in standalone net profit at Rs 139.84 crore for the quarter ended June 30. The company had posted a net profit of Rs 140.81 crore in the year-ago period. Total income stood at Rs 1,389.52 crore.
KANSAINER KNZAY 500165

0
Kansai Nerolac Paints Q1 net at Rs 139.84 crore

2018-07-20 moneycontrol
Kansai Nerolac Paints today reported a marginal decline in its net profit at Rs 139.84 crore for the quarter ended June 30.
KANSAINER KNZAY 500165

0
Kansai Nerolac Paints Limited - Financial Result Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

0
Wipro, Bajaj Auto, MCX, HDFC Life, Ceat results

2018-07-19 thehindubusinessline
Around two dozen companies including Atul, Bajaj Auto, Bajaj Holdings, Bata India, Capital Trust, Ceat, Chowgule Steamships, Diligent Media, HDFC Standard Life Insurance, Havells India, Infomedia Press, Kansai Nerolac Paints, L&T Finance Holdings, MCX, Nelco, Onward Technologies, Radhe Developers, Ramgopal Polytex, Sanwaria Consumer, Wipro and Zee Media Corporation will declare their quarterly numbers for the period ended June 2018 on Friday.
BAJAJ-AUTO RADHEDE CHOWGULSTM 517354 501833 HVLQY ONWARDTEC KNZAY 517536 532977 BATAINDIA 531273 KANSAINER 511505 HAVELLS INFOMEDIA CAPITALT 509069 500043 500165

0
Bharat Kedia is COO at Motilal PE

2018-07-18 thehindubusinessline
SME-focussed investment firm Motilal Oswal Private Equity Investment Advisors (MOPE) has appointed Bharat Kedia as Chief Operating Officer, who was previously with Zee Entertainment Enterprises as Chief Financial Officer. In addition, he has worked in firms such as Parag Milk Foods, Publicis Groupe India, Coca-Cola HBC SA, United Beverages, BDH Industries and Kansai Nerolac Paints, earlier in his career.
CCHGY 524828 CCH KANSAINER ZEEEY KNZAY 505537 BDH ZEEL 500165

0
Kansai Nerolac Paints Limited - Trading Window

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Shareholders meeting

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

11
Kansai Nerolac Paints down 2%, to acquire 55% in RAK Paints

2018-06-20 moneycontrol
Share price of Kansai Nerolac Paints declined 2.6 percent intraday Wednesday. The company entered into share purchase agreement (SPA) to acquire 55% in RAK Paints, Bangladesh.
ICICIBANK KANSAINER KNZAY 532174 IBN 500165

11
Kansai Nerolac to acquire 55% stake in RAK Paints to enter Bangladesh

2018-06-19 moneycontrol
Paint maker Kansai Nerolac today said it is in process to acquire 55 per cent equity stake in Bangladesh-based RAK Paints.
ICICIBANK KANSAINER KNZAY 532174 IBN 500165

4
Kansai Nerolac Paints Limited - Acquisition

2018-06-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Updates

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Dividend

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...